| MORPHOSYS AG | 114.05 / -1.68% |
| Date/Time | 07/13 / 11:34 |
| Chg. / Chg.(%) | -1.95 / -1.68% |
| Bid | 113.80 / 61 |
| Ask | 114.10 / 51 |
| Open | 116.20 |
| Previous Close | 116.00 |
| High | 116.20 |
| Low | 114.00 |
| Volume [EUR] | 167,361.38 |
| Volume [Units] | 1,462 |
| Price fixings | 54 |
| ISIN | DE0006632003 |
| Security | MOR/D |
| Exchange | Turquoise |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 113.95 |  |
24,852 |
| Cboe Europe .. | 114.00 | |
6,893 |
| TradeGate | 114.100 | |
3,644 |
| Turquoise | 114.05 | |
1,462 |
| Cboe Europe .. | 114.00 | |
913 |
| London Inter.. | 114.30 | |
334 |
| Stuttgart | 114.050 | |
60 |
| Hamburg | 114.50 | |
42 |
| Frankfurt | 116.0000 |  |
15 |
| gettex | 114.450 | |
11 |
| Vienna Globa.. | 115.10 | |
0 |
| Hannover | 116.25 | |
0 |
| Berlin | 116.25 | |
0 |
| München | 116.25 | |
0 |
| Düsseldorf | 116.30 | |
0 |
| Lang & Schwa.. | 113.900 | |
|
| SIX Swiss Ex.. | 102.00 | ||
| Nasdaq Other.. | 128.1500 | 100 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
09/13/2018 / 22:04 - GlobeNewswire
Real-time